导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 24.34% | 260/4773 |
| 近一周 | -5.76% | 5365/5465 |
| 近一月 | 2.63% | 206/5421 |
| 近一季 | 3.03% | 499/5231 |
| 近半年 | 1.54% | 1151/4920 |
| 近一年 | 23.57% | 377/4394 |
| 近两年 | 54.31% | 1384/2954 |
| 近三年 | 31.61% | 1032/2253 |
| 成立以来 | 84.25% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
18.69% 20/4961 |
-11.43% 4288/5312 |
- - |
- - |
| 2025 | 1.66% 3221/4813 |
-4.28% 3153/3635 |
-1.43% 3161/4076 |
6.88% 3494/4524 |
0.81% 1754/4813 |
| 2024 | 2.42% 1974/3463 |
1.62% 868/2808 |
-3.07% 1296/3014 |
7.58% 2808/3129 |
-3.34% 2330/3463 |
| 2023 | 11.15% 76/2656 |
3.19% 1243/2280 |
-4.37% 1154/2385 |
8.89% 11/2515 |
3.44% 57/2655 |
| 2022 | 13.00% 8/2207 |
20.02% 7/1919 |
9.51% 281/2016 |
-0.14% 10/2113 |
-13.91% 2073/2208 |
| 2021 | 36.56% 46/1822 |
-1.79% 542/1255 |
20.10% 153/1330 |
39.36% 3/1466 |
-16.92% 1638/1822 |
| 2020 | 29.62% 533/1250 |
-14.49% 961/1022 |
3.32% 940/1060 |
14.67% 262/1152 |
- - |
| 2019 | 15.53% 691/1092 |
24.29% 514/748 |
-4.37% 422/797 |
-5.95% 798/844 |
3.36% 837/912 |
| 2018 | -32.00% 513/834 |
- - |
- - |
- - |
-12.71% 476/691 |
| 2017 | 7.26% 320/714 |
- - |
- - |
- - |
- - |
| 2016 | 4.67% 61/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 招商中证煤炭等权指数(LOF)A VS. 长安沪深300非周期A(740101) |